Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ravidasvir + Ritonavir-boosted Danoprevir in Healthy Participants
NCT03020134Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of ravidasvir in hepatitis C (HCV) (2 arms), sponsored by Ascletis Pharma Inc. Primary endpoint: Incidence of adverse events at 40 days. Started Jul 2016; status: completed.
02
Drugs
ravidasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03020134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020134.